Genome Wide Association Metanalysis Of Skull Bone Mineral Density Identifies Loci Relevant For Osteoporosis And Craniosynostosis

Competing Interest Statement

Unnur Styrkarsdottir, Kari Stefansson and Gudmar Thorleifsson are employed by deCODE genetics/Amgen Inc

Funding Statement

ALSPAC: The UK Medical Research Council and the Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This work is supported by a Medical Research Council program grant (MC-UU-12013/4 to D.M.E). D.M.E is supported by an NHMRC Senior Research Fellowship (APP1137714). J.P.K is funded by a National Health and Medical Research Council (Australia) Investigator grant (GNT1177938). The Bone Mineral Density in Childhood Study was funded by the National Institute of Child Health and Human Development (NICHD) contracts NO1-HD-1-3228, -3329, -3330, -3331, -3332 and - 3333, R01 HD058886 and the Clinical and Translational Research Center (5-MO1-RR-000240 and UL1 RR-026314). B-PROOF is supported and funded by The Netherlands Organization for Health Research and Development (ZonMw, Grant 6130.0031), The Hague; unrestricted grant from NZO (Dutch Dairy Association), Zoetermeer; NCHA (Netherlands Consortium Healthy Ageing) Leiden/ Rotterdam; Ministry of Economic Affairs, Agriculture and Innovation (project KB-15-004-003), the Hague; Wageningen University, Wageningen; VU University Medical Center, Amsterdam; Erasmus MC, Rotterdam. deCODE genetics funded the deCODE study. ERF: The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the 5th Framework Programme (no. QLG2-CT-2002-01254). High-throughput analysis of the ERF data was supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). The musculoskeletal research of the Generation R Study is partly supported by the European Commission grant HEALTH-F2-2008-201865-GEFOS. The general design of Generation R Study is made possible by financial support from the Erasmus Medical Center, Rotterdam, the Erasmus University Rotterdam, ZonMw (ZonMw 907.00303, ZonMw 916.10159, ZonMw VIDI 016.136.367 to F.R.), the Netherlands Organisation for Scientific Research (NWO), the Ministry of Health, Welfare and Sport and the Ministry of Youth and Families. J.F.F. has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 633595 (DynaHEALTH). The study was also supported by funding from the European Unions Horizon 2020 research and innovation programme (733206, LIFECYCLE). GOOD Study: Financial support was received from the Swedish Research Council (K2010- 54X-09894-19-3, 2006-3832 and K2010-52X-20229-05-3),the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderbergs Foundation, the Västra Götaland Foundation, the Göteborg Medical Society, the Novo Nordisk foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS. MROS-USA: The Osteoporotic Fractures in Men (MrOS) Study is supported by: National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS grant numbers R01 AR051124, RC2 AR058973), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. NEO: The genotyping in the NEO study was supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. D.M-K is supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023). OPRA: This work was supported by grants from the Swedish Research Council (K2015-52X-14691-13-4), Forte (Grant 2007-2125), Greta and Johan Kock Foundation, A. Påhlsson Foundation, A. Osterlund Foundation, H Järnhardt foundation, King Gustav V 80 year fund, King Gustav V and Queen Victoria Foundation, Åke Wiberg Foundation, Thelma Zoegas Foundation, Swedish Rheumatism foundation, Skäne University Hospital Research Fund and the Research and Development Council of Region Skäne, Sweden. ORCADES: ORCADES was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), the Royal Society, the MRC Human Genetics Unit, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). PANIC: The PANIC study was financially supported by grants from Ministry of Social Affairs and Health of Finland, Ministry of Education and Culture of Finland, Finnish Innovation Fund Sitra, Social Insurance Institution of Finland, Finnish Cultural Foundation, Juha Vainio Foundation, Foundation for Pediatric Research, Paavo Nurmi Foundation, Paulo Foundation, Diabetes Research Foundation, Yrjo Jahnsson Foundation, Finnish Foundation for Cardiovascular Research, State Research Funding from Research Committee of Kuopio University Hospital Catchment Area, Kuopio University Hospital EVO Funding, National Doctoral Programs, and the City of Kuopio. RAINE: The Raine Study receives core funding support from the University of Western Australia -Faculty of Medicine, Dentistry and Health Sciences, Curtin University, the Raine Medical Research Foundation, the Women and Infants Research Foundation, Telethon Kids Institute and Edith Cowan University. The study was funded by the National Health and Medical Research Council of Australia [grant numbers 572613, 403981 and 003209], the Canadian Institutes of Health Research [grant number MOP-82893] and the Lions Eye Institute in WA. This work was supported by resources provided by the Pawsey Supercomputing Centre with funding from the Australian Government and the Government of Western Australia. Rotterdam Study: The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/NWO, NCHA (project nr. 050-060-810). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, ZonMw, RIDE, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. SOF: The Study of Osteoporotic Fractures (SOF) is supported by National Institutes of Health funding. NIA provides support under the following grant numbers: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. NIAMS provides funding for the SOF ancillary study grant number RC2AR058973. Twins UK: TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust in partnership with Kings College London. T.D.S is holder of an ERC Advanced Principal Investigator award. The study also received support from the Australian National Health and Medical Research Council (Project Grant 1048216) and The Pawsey Supercomputing Centre (with Funding from the Australian Government and the Government of Western Australia; PG 16/0162, PG 17/director2025).C.A-B: National Institute of Health /National Institute of Arthritis Musculoskeletal and Skin Diseases grant number AR060981.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval for the ALSPAC study was obtained from the ALSPAC Ethics comittee. The BMDCS study was approved by the Institutional Review Board of the Childrens Hospital of Los Angeles, Cincinnati Childrens Hospital Medical Center, Childrens Hospital of Philadelphia and Columbia University. The WU Medical Ethics Committee approved the BPROOF study. The COPSAC2000 Study was approved by the Local Ethics Committee (KF 01-289/96). The COPSAC2010 Study was approved by the Local Ethics Committee (H-B-2008-093). The COPSAC2000 and the COPSAC 2010 were approved by the Danish Data Protection Agency (2015-41-3696). The deCODE Study was approved by the Data Protection Commission of Iceland and the National Bioethics Committee of Iceland. The Medical Ethics Committee of the Erasmus University Medical Centre, approved the ERF Study, the Rotterdam Study and the Generation R Study. The GOOD study was approved by the local ethics committee at Gothenburg. The Institutional Review Board at University of Alabama at Birmingham, University of Minnesota, Stanford University, University of Pittsburgh, Oregon Health and Science University and the University of California San Diego approved the MR-OS USA Study. The Medical Ethical Committee of the Leiden University Medical Center (LUMC) approved the NEO Study. The Lund University Ethics Committee approved the OPRA Study. Ethical approval of the PANIC Study was obtained from the Research Ethics Committee of the Hospital District of Northern Savo. The University of Western Australia (UWA) has provided ethical approval of the RAINE Study. Favorable ethical opinion of the TWINSUK Study was granted by the formerly known St. Thomas Hospital Research Ethics Committee (REC). UK Biobank has ethical approval from the Northwest Multi-centre Research Ethics Committee (MREC).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes